Epelde Francisco
Internal Medicine Department, Hospital Universitari Parc Taulí, 08208 Sabadell, Spain.
Medicine Department, Facultad de Medicina, University Autonoma of Barcelona, 08193 Bellaterra, Spain.
Medicina (Kaunas). 2025 Apr 14;61(4):720. doi: 10.3390/medicina61040720.
The gut microbiota has emerged as a crucial player in cardiovascular diseases, including heart failure (HF). Recent studies have highlighted the bidirectional interaction between the gut and the heart, often referred to as the gut-heart axis. Dysbiosis, characterized by alterations in microbial composition and function, has been linked to systemic inflammation, metabolic disturbances, and impaired cardiovascular homeostasis. This review explores the mechanisms through which gut microbiota influences HF, including microbial metabolite production, inflammatory pathways, endothelial dysfunction, hormonal modulation, fluid retention, and sodium absorption. The potential therapeutic implications of microbiota modulation through diet, probiotics, and pharmacological interventions are also discussed. Understanding these mechanisms could pave the way for novel diagnostic and therapeutic strategies in the management of HF. Future research should focus on longitudinal studies to establish causality and the development of personalized microbiota-based interventions.
肠道微生物群已成为心血管疾病(包括心力衰竭,HF)中的关键因素。最近的研究强调了肠道与心脏之间的双向相互作用,通常称为肠-心轴。以微生物组成和功能改变为特征的生态失调与全身炎症、代谢紊乱以及心血管稳态受损有关。本综述探讨了肠道微生物群影响心力衰竭的机制,包括微生物代谢产物的产生、炎症途径、内皮功能障碍、激素调节、液体潴留和钠吸收。还讨论了通过饮食、益生菌和药物干预调节微生物群的潜在治疗意义。了解这些机制可为心力衰竭管理中的新型诊断和治疗策略铺平道路。未来的研究应侧重于纵向研究,以确定因果关系并开发基于个性化微生物群的干预措施。